- Home
- HAIN vs CGEN Comparison
HAIN vs CGEN Comparison
Compare HAIN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAIN
- CGEN
- Stock Information
- Founded
- HAIN 1993
- CGEN 1993
- Country
- HAIN United States
- CGEN Israel
- Employees
- HAIN N/A
- CGEN N/A
- Industry
- HAIN Packaged Foods
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HAIN Consumer Staples
- CGEN Health Care
- Exchange
- HAIN Nasdaq
- CGEN Nasdaq
- Market Cap
- HAIN 159.7M
- CGEN 167.4M
- IPO Year
- HAIN 1993
- CGEN 2000
- Fundamental
- Price
- HAIN $1.82
- CGEN $1.43
- Analyst Decision
- HAIN Hold
- CGEN
- Analyst Count
- HAIN 9
- CGEN 0
- Target Price
- HAIN $3.85
- CGEN N/A
- AVG Volume (30 Days)
- HAIN 950.0K
- CGEN 206.4K
- Earning Date
- HAIN 11-06-2025
- CGEN 08-06-2025
- Dividend Yield
- HAIN N/A
- CGEN N/A
- EPS Growth
- HAIN N/A
- CGEN N/A
- EPS
- HAIN N/A
- CGEN N/A
- Revenue
- HAIN $1,615,231,000.00
- CGEN $22,144,000.00
- Revenue This Year
- HAIN N/A
- CGEN N/A
- Revenue Next Year
- HAIN N/A
- CGEN $159.40
- P/E Ratio
- HAIN N/A
- CGEN N/A
- Revenue Growth
- HAIN N/A
- CGEN N/A
- 52 Week Low
- HAIN $1.30
- CGEN $1.13
- 52 Week High
- HAIN $9.43
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- HAIN 54.60
- CGEN 45.41
- Support Level
- HAIN $1.72
- CGEN $1.39
- Resistance Level
- HAIN $1.87
- CGEN $1.46
- Average True Range (ATR)
- HAIN 0.10
- CGEN 0.07
- MACD
- HAIN 0.00
- CGEN 0.00
- Stochastic Oscillator
- HAIN 53.57
- CGEN 38.10
About HAIN Hain Celestial Group Inc. (The)
The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas among others. It operates under two reportable segments; North America and International. The majority of its revenue is derived from the North America segment which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.